Every Form 4 that Opko Health Inc. (OPK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OPK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OPK filings page.
OPKO Health, Inc. reported that Sr. Vice President and CFO Adam Logal had 53,266 shares of common stock withheld on July 24, 2026 at $1.22 per share to satisfy tax withholding on vesting of restricted stock units. After this tax-withholding disposition, he directly owns 563,396 shares.
OPKO HEALTH, INC. executive VP-Administration and director Steven D. Rubin reported a tax-related share withholding. On 2026-07-24, 53,266 shares of common stock were withheld at $1.22 per share to satisfy tax obligations on vested restricted stock units, leaving 6,571,966 shares directly owned.
OPKO Health director Prem A. Lachman received a new stock option grant. On June 18, 2026, he was awarded options for 30,000 shares of OPKO Health common stock at an exercise price of $1.42 per share. These options are compensation-related, not an open-market purchase, and bring his directly held option position reported in this filing to 30,000 derivative shares.
OPKO Health director Roger Medel received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036. Following this grant, he holds 30,000 options directly.
OPKO HEALTH, INC. director John A. Paganelli received a grant of stock options for 30,000 shares of common stock as compensation. The options have an exercise price of $1.42 per share, become exercisable starting on 2027-06-18, and expire on 2036-06-17. Following this grant, he holds 30,000 options directly.
OPKO HEALTH, INC. director Richard C. Pfenniger Jr. received a grant of stock options representing 60,000 shares of common stock. The options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036. After this award, he holds 60,000 derivative securities directly.
OPKO HEALTH director Uppaluri Subbarao V received a grant of stock options covering 80,000 shares of common stock as part of standard director compensation. The options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036.
According to the footnote, on June 18, 2026 the company canceled a prior grant of 50,000 options, granted 30,000 new options, and reissued 50,000 options, resulting in 80,000 options held directly after this award.
OPKO HEALTH, INC. director Alice Lin-Tsing Yu received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.42 per share, were granted on June 18, 2026, and become exercisable starting June 18, 2027 with an expiration date of June 17, 2036. Following this grant, she holds stock options for 30,000 shares directly.
Opko Health director John A. Paganelli bought 10,000 shares of common stock in an open-market purchase at $1.135 per share. After this transaction, he directly holds 394,340 shares. An additional 9,175 shares are owned by his spouse, for which he disclaims beneficial ownership except for any pecuniary interest.
OPKO HEALTH, INC. director Uppaluri Subbarao V received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $1.17 per share and were awarded at no cost to the director. According to the filing, these options become exercisable on March 18, 2027 and expire on March 17, 2036. Following this grant, the director holds stock options for 50,000 underlying shares.
OPKO Health (OPK) CEO and Chairman Phillip Frost, M.D., reported multiple open-market purchases of OPKO common stock. On 11/21/2025, he bought blocks of 102,371, 3,894, 89,375, 191,490 and 192,870 shares at prices ranging from $1.30 to $1.335 per share. After these transactions, one line shows 216,706,448 shares of common stock beneficially owned indirectly as indicated in footnote (1). Separate lines show 3,568,951 shares held directly and 30,127,177 shares held indirectly as described in footnote (2).
Footnote (1) explains that certain shares are held by Frost Gamma Investments Trust and related entities, and footnote (2) explains holdings in Frost Nevada Investments Trust and related entities. In both cases, the reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
OPKO Health (OPK) insider trading report: Phillip Frost, M.D., who serves as CEO, Chairman, director and a 10% owner of OPKO Health, reported a series of open-market purchases of the company’s common stock. On 11/20/2025, he bought a total of 580,000 common shares in multiple trades at prices ranging from $1.32 to $1.35 per share, all reported as indirect ownership through Frost Gamma Investments Trust. After these transactions, one reported indirect position shows 216,126,448 shares beneficially owned. The filing also lists 3,568,951 shares held directly and an additional 30,127,177 shares held indirectly through Frost Nevada Investments Trust. The report states that beneficial ownership is disclaimed except to the extent of any pecuniary interest.
OPKO Health (OPK) insider Phillip Frost, M.D., who serves as CEO, Chairman and a 10% owner, reported multiple open market purchases of the company’s common stock. On 11/19/2025, he bought a total of 580,000 shares in several transactions at prices ranging from $1.28 to $1.32 per share. Following these transactions, he was reported as indirectly beneficially owning 215,546,448 shares through Frost Gamma Investments Trust, with additional holdings of 3,568,951 shares directly and 30,127,177 shares indirectly through Frost Nevada entities, while expressly disclaiming beneficial ownership beyond his pecuniary interest.
OPKO Health (OPK) CEO and Chairman Phillip Frost, M.D. reported multiple purchases of OPKO common stock on 11/18/2025. The transactions, coded as open-market or private purchases, ranged from $1.245 to $1.29 per share across several small trades.
Following these transactions, Frost is shown as beneficially owning 214,966,448 OPKO shares indirectly, as noted in a footnote describing Frost Gamma Investments Trust and related entities. Additional holdings of 3,568,951 shares are listed as directly owned, and 30,127,177 shares as indirectly owned through Frost Nevada Investments Trust, with both positions also accompanied by detailed ownership-disclaimer language. Frost is identified as a director, 10% owner, CEO and Chairman of OPKO Health.
OPKO Health (OPK): Phillip Frost, M.D., the company’s CEO, Chairman, Director and a 10% owner, reported an open‑market purchase of 150,000 shares of common stock on 10/31/2025 at a weighted average price of $1.4229. The price reflects multiple trades between $1.415 and $1.4299.
Following the transaction, reported beneficial ownership includes 3,568,951 shares direct, 214,386,448 shares indirect held by Frost Gamma Investments Trust, and 30,127,177 shares indirect held by Frost Nevada Investments Trust. The filing notes trust structures and standard beneficial ownership disclaimers.